See the latest open-label extension data for Ocrevus
Examine 2 years of controlled and 3+ years of open-label extension efficacy and safety data. View in Browser Important Safety Information…
Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– – Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in…
Stuart Schlossman
Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS
Published: Sep 04, 2019 Sept. 4, 2019 05:00 UTC Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal…
Stuart Schlossman
GENENTECH TO PRESENT NEW OCREVUS (OCRELIZUMAB) DATA ANALYSES SHOWING SIGNIFICANT REDUCTION OF DISABILITY PROGRESSION IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS AT THE AAN ANNUAL MEETING
New analyses show the effect of OCREVUS on reducing the risk of disability progression is associated with exposure and lower…
Stuart Schlossman
New Genentech Data at the 2019 AAN Annual Meeting Showcase Breadth and Promise of Neuroscience Portfolio
Risdiplam data from Part 1 of pivotal FIREFISH study show infants with Type 1 spinal muscular atrophy achieve key motor…
Stuart Schlossman
Pretreating Ocrevus Patients with Multiple Antihistamines and Liquids Lowers Infusion Reactions by 60%, Study Reports
December 18, 2018 Pretreating multiple sclerosis patients with antihistamines more extensively and with hydration can significantly reduce — by 60% — the likelihood…
Stuart Schlossman
Ocrevus Now Available Through NHS Scotland to Treat RRMS
Dec 12, 2018 Ocrevus (ocrelizumab, by Genentech) is now available through the National Health System (NHS) of Scotland to treat patients with…
Stuart Schlossman
OCREVUS (OCRELIZUMAB) DATA SHOW EARLY INITIATION OF TREATMENT REDUCES DISABILITY PROGRESSION OVER FIVE YEARS IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
October 10, 2018 People with relapsing MS (RMS) treated sooner with OCREVUS had earlier reduction in disease activity and less…
Stuart Schlossman
Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS
Monday, Oct 1, 2018 Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple…
Stuart Schlossman
Ocrelizumab: A Review in Multiple Sclerosis
Syed YY. CNS Drugs. 2018. Authors Syed YY1. Author information 1 Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New…
Stuart Schlossman
